TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy
0301 basic medicine
0303 health sciences
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Basic Tumor Immunology
Interferon-beta
3. Good health
Mice
03 medical and health sciences
Transforming Growth Factor beta
Cell Line, Tumor
Tumor-Associated Macrophages
Animals
Humans
Receptors, Transforming Growth Factor beta
RC254-282
DOI:
10.1136/jitc-2021-003519
Publication Date:
2022-03-17T17:11:54Z
AUTHORS (11)
ABSTRACT
Background Transforming growth factor-beta (TGFβ) can limit the efficacy of cancer treatments, including radiotherapy (RT), by inducing an immunosuppressive tumor environment. The association TGFβ with impaired T cell infiltration and antitumor immunity is known, but mechanisms which participates in immune exclusion limits therapies warrant further investigations. Methods We used clinically relevant receptor 2 (TGFβR2)-neutralizing antibody MT1 small molecule TGFβR1 inhibitor LY3200882 evaluated their combination RT against murine orthotopic models head neck lung cancer. Results demonstrated that pathway inhibition strongly increased RT. TGFβR2 upregulated interferon beta expression tumor-associated macrophages within irradiated tumors favored at periphery core lesions. highlighted both lymphocyte observed were dependent on type I signaling. Conclusions These data shed new light role limiting RT, identifying a novel mechanism involving macrophage-derived production, fostering use TGFβR therapeutic strategies for management
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (27)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....